Supplementary Table 3.
Data Elements of the COLD Study Data Collection Forms
| Variable | Category |
|---|---|
| Center-specific record ID | Identifier |
| Center name | |
| Age (at diagnosis of COVID) | |
| Gender | Male Female Other |
| Race | White African American Asian American Indian Other |
| Ethnicity | Hispanic or Latino Non-Hispanic |
| Date of data collection | |
| Home Address Zip Code | |
| Residence | Home: apartment Home: single family home Skilled nursing home Long-term care facility Assisted living facility Other Do not know None/Shelter |
| Number of people at home | |
| Insurance | Medicare/Medicaid Private insurance Uninsured Do not know |
| Date of COVID-19 diagnosis | |
| Mode of diagnosis of COVID-19 | Positive PCR test Positive serologic test Not clear Other |
| Risk factors for COVID-19 | Travel to high risk region Sick contacts Hospitalization within the past month Healthcare worker Essential worker Nursing home resident Other |
| Indication of testing | Travel to high risk region Contacts who tested positive for COVID-19 Symptoms Healthcare worker surveillance Surveillance Other |
| Hospitalization for COVID-19 | Yes No |
| Use of supplemental oxygen | Yes No |
| Use of vasopressors | Yes No |
| Number of pressors used | |
| ICU admission | Yes No |
| Mechanical ventilation | Yes No |
| Noninvasive positive pressure ventilation | Yes No |
| Length of hospital stay (days) | |
| Death related to COVID-19 | Yes No |
| Symptoms | Cough, shortness of breath, sore throat, runny nose, fatigue, myalgias, chest pain, diarrhea, nausea/vomiting, anorexia, anosmia, confusion |
| Number of years since the patient has a known diagnosis of chronic liver disease | |
| Etiology | Hepatitis C: current Hepatitis C: cured Hepatitis B Nonalcoholic fatty liver disease: hepatic steatosis alone Nonalcoholic steatohepatitis Alcoholic liver disease Cryptogenic cirrhosis Primary biliary cholangitis Primary sclerosing cholangitis Autoimmune hepatitis Hepatocellular carcinoma (HCC) Other |
| Cirrhosis | Yes No |
| Fibroscan | F0-1 F2 F3 F4 |
| Fibrosis-4 | F0-1 F2 F3 F4 |
| NAFLD fibrosis score | F0-1 F2 F3 F4 |
| MR elastography | F0-1 F2 F3 F4 |
| US elastography | F0-1 F2 F3 F4 |
| Biopsy | F0-1 F2 F3 F4 |
| Other | F0-1 F2 F3 F4 |
| Comorbidities | Diabetes Hypertension Hyperlipidemia Obesity Tobacco smoking Coronary artery disease Congestive heart Failure HIV positive COPD Asthma Non-liver malignancy Opioid use disorder Obstructive sleep apnea Chronic lung disease: non-asthma, non-COPD Vaping Marijuana use |
| Tobacco smoking status | Never smoker Former smoker (smoked at least 100 cigarettes in lifetime) Current smoker |
| Alcohol use | Do not drink currently Social drinking Daily drinking |
| Has the patient received a liver transplantation? | Yes No |
| Date of transplant | |
| Type of immunosuppression at the time of COVID-19 diagnosis | Tacrolimus Cyclosporine Prednisone (<20 mg/day) Prednisone (>21 mg/day) Mycophenolate Azathioprine mTOR inhibitors (Sirolimus, Everlolimus) |
| Did the patient receive any of these within 6 months of COVID-19 diagnosis? | Intravenous methyprednisolone Anti-thymocyte globulin (ATG) Basiliximab Rituximab |
| Other immunosuppression | |
| Was immunosuppression modified during COVID-19? | Yes No |
| How was immunosuppression modified? | |
| Did the patient experience acute rejection during COVID-19? | Yes No |
| Laboratory data (before COVID-19, at diagnosis of COVID-19, peak during COVID-19, after COVID-19) | ALT, AST, Alkaline Phosphatase, GGT, Total Bilirubin, Albumin, Creatinine, Sodium, INR, Platelets, Ferritin, WBC, Lymphocytes, Neutrophils, Triglycerides, LDL, HbA1c, CK |
| Decompensation before COVID-19 | None Ascites Variceal bleed Hepatic encephalopathy Other |
| Did the patient decompensate during COVID-19? | Yes No |
| Ascites before COVID-19 (field annotation: 1–6 months before COVID-19) | None Mild-Moderate Severe |
| Encephalopathy before COVID-19 (field annotation: 1–6 months before COVID-19) | None Mild-Moderate Severe |
| Ascites during COVID-19 | None Mild-Moderate Severe |
| Encephalopathy during COVID-19 | None Mild-Moderate Severe |
| Ascites after COVID-19 | None Mild-Moderate Severe |
| Encephalopathy after COVID-19 | None Mild-Moderate Severe |
| Did the patient develop variceal bleeding during COVID-19? | Yes No |
| Were any of the following delayed or cancelled due to diagnosis of COVID-19? | Endoscopy for esophageal varices surveillance Imaging for HCC surveillance Paracentesis for symptomatic ascites Hepatitis C treatment Hepatitis B treatment Liver transplant evaluation Liver transplantation Other |
| Were ambulatory clinic visits to hepatology delayed or canceled due to COVID-19? | Yes No |
| Were ambulatory clinic visits to primary care or other specialties delayed or cancelled due to COVID-19? | Yes No |
| Were medical procedures not related to liver disease delayed or cancelled? | Yes No |
| Was care impacted not directly by COVID-19 but because of health system overload? | Yes No |
| Did the patient have a telehealth visit during COVID-19? | Yes No |
| COVID-19 treatment | Remdesivir Chloroquine Hydroxychloroquine Azithromycin Prednisone or Methylprednisolone Lopinavir/ritonavir Donor plasma Other None |
| Did the patient receive any of the following antibiotics during COVID-19? | Amoxicillin/Clavulanate Cephalosporins Aminoglycosides Macrolides Minocycline Anti-tuberculosis drugs Fluoroquinolones Azithromycin None |
| Did the patient receive any of the following hepatotoxic medications for more than 3 days during COVID-19 infection? | Acetaminophen >2 g per day NSAIDs Anticonvulsants: Phenytoin, Valproic acid, Carbamazepine Azoles Amiodarone Anesthetics: Halothane, Isoflurane Statins Other hepatotoxic medications None |
| Was the patient chronically on any of the following medications before acquiring COVID-19 infection? | Proton pump inhibitors ACE inhibitors Angiotensin receptor blockers |
| If the patient had HCC, had they received any of the following? | Transarterial therapy Ablative therapy Tyrosine kinase inhibitors Immunotherapy None |
| Date of last follow-up | |
| Status | Alive, fully recovered Alive, still impacted by COVID-19 Death from COVID-19 Death from other causes |
ACE, angiotensin-converting enzyme; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; COLD, COVID-19 in chronic liver disease; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; GGT, gamma-glutamyl transferase; HbA1c, glycosylated hemoglobin; HIV, human immunodeficiency virus; ICU, intensive care unit; INR, international normalized ratio; LDL, low-density lipoprotein; MR, magnetic resonance; NAFLD, nonalcoholic fatty liver disease; NSAIDs, nonsteroidal anti-inflammatory drugs; PCR, polymerase chain reaction; US, ultrasound; WBC, white blood cell count.